Lung cancer is a major health issue around the world, killing more people in one year than breast cancer and ovarian cancer combined.
In Australia, lung cancer is responsible for 18.9 per cent of all cancer deaths and is the fifth most commonly diagnosed cancer in the country. Last year, around 12,741 Aussies were diagnosed with lung cancer and 9,198 people are expected to die from the disease this year alone. Despite these stats, lung cancer patients continue to face stigma, with many claiming these patients only have themselves to blame.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
